Aslan Pharma raises additional $9m led by MVP Capital Partners; closes Series C at $43m

Singapore-based Aslan Pharmaceuticals (ASLAN), a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types, has raised an additional $9 million to close its Series C financing round at $43 million.

Continue reading this story with a subscription to DealStreetAsia.

Subscribe

Should your colleagues be reading this article too? Contact us for corporate subscriptions at subs@dealstreetasia.com.